-
Product Insights
Aventicum RE/ Revelate Cap/ Valpre – 10 Newmarket Square BTR Residential Community – Leinster
The Aventicum RE/ Revelate Cap/ Valpre – 10 Newmarket Square BTR Residential Community – Leinster project involves the construction of a Build-to-Rent (BTR) residential community comprising 132 high-quality apartment units in the 10 Newmarket Square area of the Liberties in Dublin 8, Leinster, Ireland. Equip yourself with the essential tools needed to make informed and profitable decisions with our Aventicum RE/ Revelate Cap/ Valpre – 10 Newmarket Square BTR Residential Community – Leinster report. Note: This is an on-demand report...
-
Product Insights
D-16 Mine (Revelation Energy, LLC)
The D-16 Mine (Revelation Energy, LLC) is a coal mine in United States. It is currently in operation. Empower your strategies with our D-16 Mine (Revelation Energy, LLC) report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in B-Cell Non-Hodgkin Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
Myocarditis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocarditis - Drugs In Development, 2023’, provides an overview of the Myocarditis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Food Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘Food Allergy - Drugs In Development, 2023’, provides an overview of the Food Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Food Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HMPL-760 in Tenosynovial Giant Cell Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HMPL-760 in Tenosynovial Giant Cell Tumor Drug Details: HMPL-760 is under development for the treatment...